Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva Off-Label Marketing Caused 'Earlier' Death, DOJ Alleged

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche and OSI Pharmaceuticals to pay $67m to resolve claims they misrepresented Tarceva effectiveness, diverting patients from first-line treatments and causing them to "die earlier and faster;" in other late-week legal developments, Salix settles kickback claims and former sales reps seemingly from Insys are arrested for fentanyl kickbacks.

Advertisement

Related Content

Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
Pharma Deals With The DOJ

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel